Autophagy Is a Potential Target for Enhancing the Anti-Angiogenic Effect of Mebendazole in Endothelial Cells. (2019)

Peer-Reviewed Study · So Jung Sung; Hyun-Kyung Kim; Yong-Kil Hong et al. · January 1, 2019

So Jung Sung et al., 2019-01-01: Endothelial-cell study of mebendazole's anti-angiogenic action, finding growth-factor-independent inhibition of proliferation, migration and tube formation plus protective autophagy.

Treatment of ECs with MBZ led to inhibition of EC proliferation in a dose-dependent manner in several culture conditions in the presence of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) or FBS, without selectivity of growth factors, although MBZ is known to inhibit VEGF receptor 2 kinase.

So Jung Sung et al., 2019-01-01: Endothelial-cell study of mebendazole's anti-angiogenic action, finding growth-factor-independent inhibition of proliferation, migration and tube formation plus protective autophagy. Study type: human endothelial cell culture. N: not applicable. Country: Korea (Catholic University of Korea, Seoul). Dose: not stated in the abstract text captured. Funder: not stated in the record. Declared conflicts: not stated in the record. PARTLY because the paper reports that mebendazole inhibits endothelial cells without selectivity for VEGF, which cuts against a VEGFR2-specific account of its anti-angiogenic effect.